Core Viewpoint - AMG announces the retirement of Karen L. Alvingham from its Board of Directors and the appointment of G. Staley Cates, effective April 1, 2026, highlighting a transition in leadership and continued commitment to long-term value creation [2][4]. Group 1: Board Changes - G. Staley Cates will join AMG's Board of Directors on April 1, 2026, bringing extensive experience from his tenure at Southeastern Asset Management [2][3]. - Karen L. Alvingham, who has served on the Board since January 2018, will retire on the same date, with appreciation expressed for her contributions during a significant growth period for AMG [2][4]. Group 2: Leadership and Strategy - Jay C. Horgen has been re-appointed as President, effective April 1, 2026, and will continue in his role as Chief Executive Officer, indicating stability in leadership [4]. - AMG's strategy focuses on generating long-term value by investing in high-quality independent partner-owned firms, with a reported aggregate assets under management of approximately $813 billion as of December 31, 2025 [5].

Core Insights - Aclaris Therapeutics reported positive interim results from its Phase 1a trials for the bispecific antibody ATI-052, indicating strong safety and tolerability, with complete results expected in Q2 2026 [1][3] - The company has initiated Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma, with top line results anticipated in the second half of 2026 [1][2] - Aclaris plans to file an Investigational New Drug (IND) application for its lead ITK inhibitor candidate, ATI-9494, in the second half of 2026 [1][12] Pipeline Developments - Positive interim results from the Phase 1a SAD/MAD trial of ATI-052 showed a favorable safety profile and robust target engagement, supporting potential extended dosing every three months [3][2] - Two Phase 1b POC trials for ATI-052 have been initiated, with results expected in the latter half of 2026 [3][2] - Planning for a Phase 2b program for ATI-052 is underway, targeting asthma and atopic dermatitis as initial indications [3] Financial Performance - Aclaris reported a net loss of $19.8 million for Q4 2025, a significant decrease from a net loss of $96.6 million in Q4 2024 [7] - Total revenue for Q4 2025 was $1.3 million, down from $9.2 million in Q4 2024, primarily due to a prior commercial milestone [8] - Research and development expenses increased to $16.6 million in Q4 2025 from $9.0 million in the prior year, driven by higher costs associated with product candidate development [9] Liquidity and Capital Resources - As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million, down from $203.9 million in 2024 [6][20] - The company believes its current financial resources will be sufficient to fund operations into the second half of 2028 [6]

Fourth Quarter HighlightsFourth quarter sales totaled $1.49 billion, up 13.2% driven by acquisitionsCompleted SPI Acquisition Full Year HighlightsCompleted seven acquisitions, adding approximately $1.2 billion in annual salesReturned $434.2 million in capital to stockholders through the repurchase of ~1.4 million shares 2026 OutlookExpects 2026 sales between $5.925 to $6.225 billion andadjusted EBITDA in the range of $1.005 billion to $1.155 billionAcquisitions continue to be top priority for deploying capi ...

Core Insights - Playtika Holding Corp. reported a revenue of $678.8 million for Q4 2025, reflecting a 0.6% increase sequentially and a 4.4% increase year-over-year [9] - Direct-to-Consumer (DTC) revenue reached $250.1 million, marking a 19.5% sequential increase and a 43.2% year-over-year increase [9] - The company experienced a net loss of $(309.3) million, attributed to non-cash impacts from contingent consideration remeasurement related to the SuperPlay acquisition [9][20] - Adjusted net income was reported at $89.0 million, while adjusted EBITDA was $201.4 million, showing a 9.5% year-over-year increase despite a 7.4% sequential decrease [9][34] Q4 2025 Financial Highlights - Revenue for Q4 2025 was $678.8 million, compared to $650.3 million in Q4 2024 [20] - DTC revenue for the quarter was $250.1 million, up from $174.1 million in the previous quarter [9] - Adjusted EBITDA for Q4 2025 was $201.4 million, with an adjusted EBITDA margin of 29.7% [29] FY2025 Financial Highlights - Total revenue for FY2025 was $2,755.4 million, an increase from $2,549.3 million in FY2024 [9] - DTC revenue for FY2025 was $814.5 million, compared to $694.2 million in FY2024 [9] - The company reported a net loss of $(206.4) million for FY2025, a decline from a net income of $162.2 million in FY2024 [9] Operational Metrics - Average Daily Paying Users (DPUs) increased to 357 thousand, a 0.8% sequential increase and a 5.3% year-over-year increase [10] - Average Payer Conversion improved to 4.5%, up from 4.3% in Q3 2025 and 4.2% in Q4 2024 [10] Capital Allocation Framework - The company updated its capital allocation framework, suspending its quarterly dividend to prioritize high-return uses of capital while maintaining buybacks [6] Financial Outlook - For FY2026, Playtika expects revenue to be between $2.70 billion and $2.80 billion, with adjusted EBITDA projected between $730 million and $770 million [7]

Core Viewpoint - Enovis Corporation reported its financial results for Q4 and the full year of 2025, highlighting a net sales growth but significant losses due to goodwill impairment charges. Financial Results Summary Fourth Quarter 2025 - Net sales reached $576 million, reflecting a 3% increase on a reported basis and 2% on an organic basis compared to Q4 2024 [2] - The Global Reconstructive segment saw a 7% increase in net sales on a reported basis, with 3% organic growth, while the Prevention & Recovery segment experienced a 1% decline on a reported basis and remained flat organically [2] - The company reported a net loss from continuing operations of $519 million, which included a non-cash goodwill impairment charge of $501 million [3][4] - Adjusted EBITDA for the quarter was $112 million [3] Full Year 2025 - Total net sales for the year amounted to $2.2 billion, marking a 7% increase on a reported basis and 6% on an organic basis [5] - The Reconstructive segment grew by 10% on a reported basis and 8% organically, while the Prevention & Recovery segment grew by 4% on both bases [5] - The full year net loss from continuing operations was $1,182 million, which included a non-cash goodwill impairment charge of $1,050 million [6] - Adjusted EBITDA for the full year was reported at $403 million [6] Management Commentary - The CEO of Enovis stated that 2025 was a year of meaningful operational progress, with advancements in integration priorities and above-market organic growth [7] - The company aims to maintain a disciplined focus on commercial execution, innovation, operational efficiency, and financial discipline as it moves into 2026 [8] 2026 Financial Outlook - Enovis expects revenue for 2026 to be in the range of $2.31 to $2.37 billion, reflecting 4-6% organic revenue growth [8] - Adjusted EBITDA is anticipated to be between $425 million and $435 million, with adjusted earnings per share projected to be between $3.52 and $3.73 [8]

Core Insights - Eos Energy Enterprises, Inc. reported a structural turning point in 2025, with accelerated production and a strengthened cash position exceeding $600 million, despite not meeting revenue expectations [4][5][6] Fourth Quarter Highlights - Achieved record quarterly revenue of $58.0 million, a 90% increase from the previous quarter and approximately 8 times year-over-year [5][6] - Secured over $240 million in new orders, totaling nearly 1.1 GWh from eight customers, indicating diversified market demand [5][10] - Ended the year with a cash balance of $624.6 million, supporting ongoing operations [5][12] Full Year 2025 Highlights - Total revenue for 2025 reached $114.2 million, more than 7 times that of 2024, driven by increased production and a 609% rise in customer deliveries [6][10] - Order backlog increased to $701.5 million, representing 2.8 GWh, a 9% sequential increase, reflecting strong commercial momentum [6][10] - The commercial opportunity pipeline grew to $23.6 billion, a 4% increase from the previous quarter and a 64% increase year-over-year [6][10] Operational Performance - Eos achieved an annual production capacity of 2 GWh, with significant operational execution improvements in the second half of 2025 [8][10] - Launched Indensity™, a next-generation energy storage architecture designed to deliver up to 1 GWh per acre, enhancing flexibility and safety [9][10] Financial Metrics - Gross loss for Q4 was $54.4 million, with a 230-point margin improvement year-over-year [6][10] - Net loss attributable to shareholders for 2025 totaled $120.5 million, with an adjusted EBITDA loss of $71.5 million, reflecting operational efficiencies [6][10] - The company retired $200 million of convertible notes, reducing annual interest expenses and extending debt maturities [14]

Core Viewpoint - Equinox Gold Corp. has announced a normal course issuer bid (NCIB) to repurchase up to 39,414,095 common shares, representing approximately 5% of its issued shares, to enhance shareholder value and reflect the company's underlying potential [1][2][3] Financial Position - The company has reduced its debt by over US$1.1 billion since Q2 2025, strengthening its balance sheet and enabling the initiation of a quarterly cash dividend of US$0.015 per share [2] - Equinox Gold expects to generate sufficient free cash flow in 2026 to support both the share repurchase and the dividend, indicating a strong financial position [3] Share Repurchase Program - The NCIB will allow purchases at prevailing market prices over a 12-month period starting March 2, 2026, with a maximum daily purchase limit of 660,178 common shares [1][3] - All shares repurchased under the NCIB will be cancelled, and the actual number and timing of purchases will depend on market conditions and management's discretion [4] Automatic Share Purchase Plan (ASPP) - The company plans to implement an automatic share purchase plan (ASPP) to facilitate share repurchases during regulatory black-out periods, allowing for continuous repurchase activity [5] - The ASPP will operate under the terms set by the company and will terminate when the NCIB expires [5]

ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and ca ...

Core Insights - Neinor Homes achieved significant operational and financial results in FY25, with total revenues reaching €697 million and notarizing 2,901 housing units [1][2] Group 1: Operational Performance - The company notarized 2,901 housing units in FY25, with 1,891 from its fully owned portfolio and 1,010 from the Asset Management business [1] - The acquisition of a 79.2% stake in AEDAS was a key factor in Neinor's operational success, marking the largest residential transaction in Spain in over a decade [2] Group 2: Financial Strength - Neinor reported a net income of €122 million for FY25, demonstrating strong financial performance and scalability [2] - The company expanded its land bank to 38,000 units, enhancing its growth potential and earnings visibility [2] Group 3: Strategic Focus - The management emphasized a clear focus on capital allocation, balance sheet strength, and sustainable shareholder returns [2] - Neinor aims to leverage its scale and disciplined execution to lead in the evolving market shaped by AI and technological changes [2]

Core Insights - ING has published its 2025 Annual Report, highlighting its strategy, business activities, and performance over the past year, with a focus on providing superior value to customers and prioritizing sustainability [1][2] Financial Performance - The bank has demonstrated resilience across various metrics despite a challenging global environment, as noted by chairman Karl Guha and CEO Steven van Rijswijk in their letter to stakeholders [2] Sustainability Initiatives - ING aims to integrate sustainability into its core operations, with its ESG rating upgraded from 'AA' to 'AAA' by MSCI in October 2025, indicating strong management of ESG material risk [6] - As of June 2025, ING's ESG risk rating is 18.0, categorized as low risk, reflecting the bank's commitment to sustainable finance [6] Corporate Governance - The 2025 Annual Report includes sections on risk management and corporate governance, ensuring transparency and accountability in its operations [2] Accessibility of Information - The 2025 Annual Report and related documents are available for download on ING's official website, providing stakeholders with comprehensive insights into the bank's performance and strategies [2]